AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00006011
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03492944
Drug: Ultrasound Microbubble Contrast Agent
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
Trial: NCT01639560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo tablet twice per day for 12 weeks and brief behavioral counseling
Trial: NCT01001338
Drug: RDEA594
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uricosuric agent for the treatment of gout.
Trial: NCT01001338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT01160289
Drug: LY2452473
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily for 12 weeks
Trial: NCT01160289
Drug: placebo (tadalafil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily for 12 weeks
Trial: NCT01160289
Drug: placebo (LY2452473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily for 12 weeks
Trial: NCT01393145
Drug: Seretide Diskus (salmeterol/fluticasone) 50/250 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses
Trial: NCT01090180
Drug: Placebo (sugar pill)
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive
Trial: NCT04458675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A biodegradable capsule, which visually similar to the Vibrant active capsule
Trial: NCT02875886
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined with hydrochlorothiazide
Trial: NCT01015547
Drug: Methotrexate alone
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
Trial: NCT01876108
Drug: H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks.
Trial: NCT04470973
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive amikacin as part of standard care.
Trial: NCT01201642
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone as 5 mg tablets will be given as a single dose of 40 mg daily for 10 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
Trial: NCT05596071
Drug: Sufentanil Citrate
RxNorm normalized name: Sufentanil Citrate
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative loading dose of sufentanil 0.6μg/kg, each additional hour 10μg, within one hour of the end of surgery to stop additional.Postoperative analgesia pump formula: sufentanil 150ug + 0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml
Trial: NCT01452373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo DHEA capsules (2) + placebo acolbifene capsule (1); daily oral dosing for 12 weeks.
Trial: NCT01247285
Drug: Fluoxetine Hydrochloride
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 mg Capsules
Trial: NCT01247285
Drug: PROZAC WEEKLY®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg Capsules
Trial: NCT01884948
Drug: Omegaven™
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00944515
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet or syrup 3 days/week
Trial: NCT00944515
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin 3 days/week
Trial: NCT00254046
Drug: TMC125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 X100 mg tablets b.i.d.96 weeks
Trial: NCT00254046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets b.i.d.96 weeks
Trial: NCT03908957
Drug: Ga68-Dolacga Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ga68-Dolacga Injection, 3.5±0.25 mCi, single dose iv
Trial: NCT00858364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously once every 3 weeks
Trial: NCT01710020
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 10 mg oral powder for constitution
Trial: NCT02984982
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT02984982
Drug: Antiplatelets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet or capsule~Route of administration: oral
Trial: NCT02984982
Drug: Anticoagulants
RxNorm normalized name: ANTICOAGULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet or capsule~Route of administration: oral
Trial: NCT04716335
Drug: Placebo (Harmine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Harmine
Trial: NCT04061044
Drug: Ophthalmic Insert
RxNorm normalized name: OPHTHALMIC INSERT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Travoprost, 0.32 mg
Trial: NCT02615002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01917279
Drug: Docetaxel plus Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.~For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase.
Trial: NCT01917279
Drug: Intermittent Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle
Trial: NCT01917279
Drug: Metronomic Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
Trial: NCT01823939
Drug: iOWH032
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Participants will be randomized at a 3:1 ratio to receive treatment with iOWH032 or placebo. A randomisation code will be generated. Each participant will be assigned the next participant number available and thereby will be assigned randomly. Active treatment will consist of an oral tablet containing 300 mg of iOWH032. The placebo will consist of identical looking tablets.~Part B: There will be no randomization during this trial. All eligible patients will receive 300 mg of iOWH032.
Trial: NCT02524054
Drug: Aerosolized saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
Trial: NCT00006015
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/sq m IV push weekly for 3 weeks, followed by a 1 wk break
Trial: NCT00006015
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/sq m IV infusion over 2 hours weekly for 3 weeks, then a 1 wk break
Trial: NCT00781053
Drug: P144 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P144 cream 0.03% will be used once a day during the whole extension period of 6 months. The patient will apply the cream by him/herself or with a help of a person uniformly in a 10% maximum affected surface until absorption
Trial: NCT00866905
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 IV infusion per institutional guidelines on day 1 of a 21 day cycle for 6 cycles
Trial: NCT03026946
Drug: Alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
Trial: NCT00948766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.
Trial: NCT00203801
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00683423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, once daily, 3 weeks treatment period, 2 weeks washout, and 2 weeks follow-up
Trial: NCT00537654
Drug: Treatment sequence A
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fed state
Trial: NCT00537654
Drug: Treatment sequence B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fed state
Trial: NCT00537654
Drug: Treatment sequence C
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fasted state
Trial: NCT00537654
Drug: Treatment sequence D
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fasted state
Trial: NCT04085185
Drug: IBI110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI110 will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
Trial: NCT00485862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02979704
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 45 patients will be treated with rosuvastatin at a dose of (5-10) mg orally once daily dose for 08 weeks
Trial: NCT00909168
Drug: FLAIMy - Fluda, Ida, Ara-C, Mylotarg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLUDARABINE: 25 mg/m2/day, 250 FS in 30', start h 9 - 1, 2, 3, 4, 5~ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5~IDARUBICIN: 10 mg/m2/day, 100 FS in 1 h, start h 16 - 1, 3, 5~GEMTUZUMAB OZOGAMICIN (Mylotarg): 5 mg, single dose 500 FS in 4 h - 6
Trial: NCT04264208
Drug: 68-Ga RM2.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET radiopharmaceutical
Trial: NCT04264208
Drug: 68-Ga PSMA11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET radiopharmaceutical
Trial: NCT03456466
Drug: TQB2303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375mg/m2 ，iv
Trial: NCT00652444
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.
Trial: NCT02135354
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * From day 1 up to and including day 3: 500 mg azithromycin PO once a day~* From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
Trial: NCT02135354
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * From day 1 up to and including day 3: 500 mg placebo PO once a day~* From day 4 up to and including day 90: 250 mg placebo PO once every 2 days
Trial: NCT03403569
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to appropriate ART, placebo oral tablets will be given to patients in the experimental group at a dosage of 2 pills three times a day per os for 12 months.
Trial: NCT00652444
Drug: Placebo (Unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching ezetimibe placebo
Trial: NCT04157010
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01219543
Drug: AZD1480 BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Dose, Capsule, BID Dosing
Trial: NCT01255215
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: Gas (inhalational) Dose: 80 ppm Dosing schedule: Continuous Treatment period: Maximum 72 hours (may be discontinued earlier if patient recovers and no longer tolerates face mask)
Trial: NCT01705938
Drug: SP-333
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02806440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT02027025
Drug: SPARC Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02078908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 2 hour infusion of sodium chloride, 25 ml/hour
Trial: NCT03427853
Drug: LY06006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY06006 18mg, 60mg, 120mg subcutaneous injection
Trial: NCT00003288
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04467840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
Trial: NCT03427853
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection
Trial: NCT01542450
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
Trial: NCT00567034
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose placebo, 1 capsule every day for 12 weeks
Trial: NCT02713178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline.
Trial: NCT02557399
Drug: Duac® fixed dose combination gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.
Trial: NCT02557399
Drug: ADA 0.1% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADA 0.1% gel containing 0.1% of adapalene.
Trial: NCT02557399
Drug: CLDM 1% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).
Trial: NCT01038622
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day placebo treatment
Trial: NCT02071095
Drug: Arm B: Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
Trial: NCT03748992
Drug: gNO
RxNorm normalized name: MAGNOLOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a proof-of-concept study in which all subjects will be treated with gNO (i.e. no control) to see if there can be a microbiological effect by conversion to negative sputum cultures and how long that effect can be sustained following treatment.~Participants will be treated for 3 weeks (5 days per week), Monday through Friday, and followed monthly for 3 months.~The treatment period includes a physical exam, vital signs, blood tests, echocardiogram, spirometry test, sputum sample, questionnaires, and the inhalation gas treatment. During the inhalation gas treatment, participants will wear a face mask (similar to an oxygen mask) and will be given nitric oxide gas through the participants nose for three treatments with fifty minutes each time. They will then be followed up monthly during the Follow-up period with tests that include a physical exam and questionnaires.
Trial: NCT04190355
Drug: 5.25% NaOCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.25% NaOCl solution
Trial: NCT04554589
Drug: Glycopyrrolate 0.2 MG
RxNorm normalized name: glycopyrrolate 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injections
Trial: NCT04554589
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT02151617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
Trial: NCT02151617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily dosing for 14 days
Trial: NCT02151617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet one time once without a meal, followed by once daily dosing for 14 days
Trial: NCT02151617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, once daily, 14 days
Trial: NCT00871156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00333567
Drug: Lumiracoxib
RxNorm normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03779451
Drug: 17-OHPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 26-28 week and up to 37-weeks' gestation or delivery.
Trial: NCT04036721
Drug: Prolonged glucocorticosteroid (prednisone) regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolongation of maintenance therapy with prednisone of patients with pneumonitis inducted by anyi-PD-1/anti-PD-L1 antibodies.
Trial: NCT04036721
Drug: Short glucocorticosteroid (prednisone) regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednison regimen based upon American Society of Clinical Oncology and European Society for Medical Oncology Clinical Practice Guidelines on pneumonitis treatment in patients receiving immunotherapy agents
Trial: NCT03163407
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
Trial: NCT04030598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching solution administered SC
Trial: NCT01283100
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg once every 24 hours for 7 days
Trial: NCT01283100
Drug: GSK2248761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg once every 24 hours for 7 days
Trial: NCT01921010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arm Description
Trial: NCT00284921
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00606307
Drug: ITF2357
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg b.i.d. PO every day. More precisely, ITF2357 was supplied as 50 mg hard gelatine capsules for oral administration.
Trial: NCT02439034
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen\* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.
Trial: NCT02563899
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. 2 mg of the vehicle will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of vehicle applied daily to both axillae is expected to range between approximately 204 and 680 mg.